![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: STK38L |
Gene summary for STK38L |
![]() |
Gene information | Species | Human | Gene symbol | STK38L | Gene ID | 23012 |
Gene name | serine/threonine kinase 38 like | |
Gene Alias | NDR2 | |
Cytomap | 12p11.23 | |
Gene Type | protein-coding | GO ID | GO:0006464 | UniProtAcc | Q9Y2H1 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
23012 | STK38L | LZE4T | Human | Esophagus | ESCC | 5.76e-06 | 1.59e-01 | 0.0811 |
23012 | STK38L | LZE5T | Human | Esophagus | ESCC | 9.49e-03 | 3.89e-01 | 0.0514 |
23012 | STK38L | LZE7T | Human | Esophagus | ESCC | 2.67e-06 | 5.49e-01 | 0.0667 |
23012 | STK38L | LZE8T | Human | Esophagus | ESCC | 2.02e-12 | 4.27e-01 | 0.067 |
23012 | STK38L | LZE20T | Human | Esophagus | ESCC | 8.58e-07 | 9.04e-02 | 0.0662 |
23012 | STK38L | LZE24T | Human | Esophagus | ESCC | 3.67e-08 | 4.33e-01 | 0.0596 |
23012 | STK38L | LZE21T | Human | Esophagus | ESCC | 3.91e-05 | 1.50e-01 | 0.0655 |
23012 | STK38L | P1T-E | Human | Esophagus | ESCC | 1.16e-02 | 1.28e-01 | 0.0875 |
23012 | STK38L | P2T-E | Human | Esophagus | ESCC | 2.14e-34 | 7.34e-01 | 0.1177 |
23012 | STK38L | P4T-E | Human | Esophagus | ESCC | 3.78e-31 | 1.18e+00 | 0.1323 |
23012 | STK38L | P5T-E | Human | Esophagus | ESCC | 6.51e-04 | 9.96e-02 | 0.1327 |
23012 | STK38L | P8T-E | Human | Esophagus | ESCC | 8.90e-35 | 6.83e-01 | 0.0889 |
23012 | STK38L | P9T-E | Human | Esophagus | ESCC | 2.12e-09 | 1.71e-01 | 0.1131 |
23012 | STK38L | P10T-E | Human | Esophagus | ESCC | 7.55e-21 | 3.74e-01 | 0.116 |
23012 | STK38L | P12T-E | Human | Esophagus | ESCC | 3.55e-36 | 7.54e-01 | 0.1122 |
23012 | STK38L | P15T-E | Human | Esophagus | ESCC | 1.61e-08 | 3.17e-01 | 0.1149 |
23012 | STK38L | P16T-E | Human | Esophagus | ESCC | 1.45e-90 | 2.10e+00 | 0.1153 |
23012 | STK38L | P17T-E | Human | Esophagus | ESCC | 4.22e-05 | 1.50e-01 | 0.1278 |
23012 | STK38L | P19T-E | Human | Esophagus | ESCC | 3.59e-04 | 5.95e-01 | 0.1662 |
23012 | STK38L | P20T-E | Human | Esophagus | ESCC | 6.98e-13 | 4.59e-01 | 0.1124 |
Page: 1 2 3 4 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00182099 | Esophagus | ESCC | peptidyl-serine modification | 196/8552 | 338/18723 | 3.07e-06 | 3.47e-05 | 196 |
GO:001810515 | Esophagus | ESCC | peptidyl-serine phosphorylation | 184/8552 | 315/18723 | 3.22e-06 | 3.61e-05 | 184 |
GO:00182098 | Oral cavity | OSCC | peptidyl-serine modification | 175/7305 | 338/18723 | 1.09e-06 | 1.46e-05 | 175 |
GO:001810510 | Oral cavity | OSCC | peptidyl-serine phosphorylation | 164/7305 | 315/18723 | 1.51e-06 | 1.99e-05 | 164 |
GO:001810514 | Oral cavity | EOLP | peptidyl-serine phosphorylation | 84/2218 | 315/18723 | 3.32e-13 | 1.05e-10 | 84 |
GO:001820914 | Oral cavity | EOLP | peptidyl-serine modification | 87/2218 | 338/18723 | 1.07e-12 | 2.46e-10 | 87 |
GO:001810522 | Oral cavity | NEOLP | peptidyl-serine phosphorylation | 70/2005 | 315/18723 | 1.97e-09 | 1.24e-07 | 70 |
GO:001820922 | Oral cavity | NEOLP | peptidyl-serine modification | 72/2005 | 338/18723 | 7.84e-09 | 4.09e-07 | 72 |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
STK38L | SNV | Missense_Mutation | novel | c.746N>C | p.Asn249Thr | p.N249T | Q9Y2H1 | protein_coding | tolerated(0.08) | benign(0.297) | TCGA-AG-A002-01 | Colorectum | rectum adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
STK38L | SNV | Missense_Mutation | c.743G>T | p.Arg248Ile | p.R248I | Q9Y2H1 | protein_coding | deleterious(0.01) | probably_damaging(0.925) | TCGA-AP-A056-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
STK38L | SNV | Missense_Mutation | c.1075N>T | p.Leu359Phe | p.L359F | Q9Y2H1 | protein_coding | tolerated(0.4) | benign(0.076) | TCGA-AP-A059-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
STK38L | SNV | Missense_Mutation | c.299N>T | p.Ala100Val | p.A100V | Q9Y2H1 | protein_coding | deleterious(0) | possibly_damaging(0.651) | TCGA-AP-A0LM-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | cisplatin | SD | |
STK38L | SNV | Missense_Mutation | rs761591925 | c.608C>T | p.Ala203Val | p.A203V | Q9Y2H1 | protein_coding | deleterious(0.01) | benign(0.067) | TCGA-AP-A1DV-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
STK38L | SNV | Missense_Mutation | c.1075C>A | p.Leu359Ile | p.L359I | Q9Y2H1 | protein_coding | tolerated(0.37) | benign(0.055) | TCGA-AP-A1DV-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
STK38L | SNV | Missense_Mutation | novel | c.985C>A | p.Gln329Lys | p.Q329K | Q9Y2H1 | protein_coding | tolerated(0.2) | benign(0.344) | TCGA-AP-A1E0-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | paclitaxel | SD |
STK38L | SNV | Missense_Mutation | novel | c.482G>T | p.Arg161Met | p.R161M | Q9Y2H1 | protein_coding | tolerated(0.13) | benign(0.027) | TCGA-AX-A2HC-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | paclitaxel | PD |
STK38L | SNV | Missense_Mutation | novel | c.1052C>A | p.Ser351Tyr | p.S351Y | Q9Y2H1 | protein_coding | deleterious(0) | probably_damaging(0.992) | TCGA-AX-A2HC-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | paclitaxel | PD |
STK38L | SNV | Missense_Mutation | c.119N>G | p.Glu40Gly | p.E40G | Q9Y2H1 | protein_coding | tolerated(0.33) | benign(0.005) | TCGA-B5-A11E-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
Page: 1 2 3 4 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
23012 | STK38L | DRUGGABLE GENOME, KINASE, ENZYME, SERINE THREONINE KINASE | inhibitor | 249565890 | ||
23012 | STK38L | DRUGGABLE GENOME, KINASE, ENZYME, SERINE THREONINE KINASE | inhibitor | HESPERADIN | HESPERADIN | 19035792 |
Page: 1 |